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Edited by Robert BaroukiAbstract This review examines the common theme of adaptive
responses of bHLH/PAS proteins, using the dioxin receptor as a
prototype. The bHLH/PAS family of transcriptional regulators
are a group of key developmental and environmental stress sens-
ing proteins. They employ a variety of post-translational control
mechanisms to regulate their transcriptional output. Amongst
this family, the dioxin receptor is best known for its ability to eli-
cit toxic responses to dioxin and dioxin like chemicals even
though it mediates more benign adaptive responses to non-toxic
xenobiotics. We discuss what is known about dioxin receptor
physiology, both adaptive and inherent, along with its molecular
regulation and put this into the context of the wider bHLH/PAS
family. We also raise the issue of its toxic responses, in particu-
lar the idea that it is the dysregulation of its poorly characterised
housekeeping functions that leads to these outcomes.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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1.1. The bHLH/PAS family of transcriptional regulators
The bHLH/PAS (basic helix-loop-helix/PER ARNT Sim)
family of proteins are grouped due to their shared structural
motifs and are characterised as transcriptional regulators. A
number of the members of this family have important roles
in adaptive responses to generalised and cellular stress. Those
members involved in stress response also play key developmen-
tal roles.
The common domain organisation is of a basic region pres-
ent within the N-terminal end of the ﬁrst helix in the helix-
loop-helix motif followed by two PAS domains and a poorly
conserved C-terminus (Fig. 1) (although some exceptions to
this arrangement arise from splice variants). The bHLH is a
motif common to a wide range of transcription factors all of
which bind deoxyribonucleic acid (DNA) as dimers. The basic
region is responsible for direct contact with DNA and the
HLH serves as the dimerisation interface. The PAS domain
serves as a secondary dimerisation domain dictating partner
speciﬁcity and increasing the strength of dimerisation (re-
viewed in [1]). The dioxin receptor (DR or AhR (aryl-hydro-
carbon receptor)) PAS domain has also, recently, been
demonstrated to exhibit intramolecular interaction with the
bHLH. This interaction may underpin high aﬃnity DNA
binding and DNA bending observed for the DR [2], further
diﬀerentiating the bHLH/PAS family from other bHLH tran-
scription factors. bHLH/PAS proteins fall into two classes
based on their dimerisation potential. Class I factors are only
capable of hetero-dimerisation with class II factors, which are
capable of both hetero- and homo-dimerisation and therefore
form obligate partners for class I factors (Fig. 1). Class I mem-
bers serve as the transcriptional regulatory unit (e.g. DR or
HIFa (hypoxia inducible factor’s)) which senses stimulatory
cues and transmits these signals to the nucleus. Class II factors
are constitutively nuclear and are absolutely required to
achieve a DNA binding form and hence transcriptional com-
petency. Current evidence suggests that class II factors may
be capable of some signal sensing (eg, protein kinase A and
C modulation of ARNT (aryl-hydrocarbon receptor nuclear
translocator) activity [3]), but it is generally accepted that these
factors simply serve as partner factors for the signal sensing
class I factors.blished by Elsevier B.V. All rights reserved.
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Fig. 1. The bHLH/PAS family of transcriptional regulators. Presented is a schematic representation of some of the bHLH/PAS family. PAS family
members have in common an N-terminal bHLH DNA binding/dimerisation domain (with the exception of PER which lacks the basic DNA binding
domain). The centralised PAS domain functions as a secondary dimerisation domain to enhance interactions between family members in addition to
providing speciﬁcity between family members, such that members in the Class I signal sensing/responsive unit and are obligated to heterodimerise
with a Class II family member. The PAS domain consists of two hydrophobic repeat regions A and B and in the case of the DR, PAS-B functions as a
ligand binding domain.
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variety of multicellular animals including molluscs, arthro-
pods, nematodes (see [4] and references therein) and a variety
of vertebrates including mammals (for example see review [5]).
So far none have been identiﬁed in prokaryotes, yeast, plants,
protozoa or diploblasts suggesting this family of proteins arose
during the appearance of the ﬁrst triploblasts. The key struc-
tural elements of this family are ancient in origin, bHLH-con-
taining proteins being found in plants and yeast and proteins
containing PAS domains identiﬁed in all kingdoms. This sug-
gests that these transcription factors may have arisen as a re-
sult of, or to accommodate, increased complexity of body plan.
The following is a brief description of several of the bHLH/
PAS family members, focussing on those members that display
a high level of regulation to control target gene output. The
control mechanisms employed to modulate the activity of
members of this protein family include novel forms of post
translational modiﬁcation, regulated nuclear import mecha-
nisms, regulation of the ability of these factors to interact with
transcriptional machinery and upregulation of target genes
which act in negative feedback loops. Such a high level of con-
trol underpins the importance of these factors in adaptive reg-
ulation of physiological processes.1.2. Hypoxia inducible factors
Among the bHLH/PAS family members, the hypoxia induc-
ible factors (HIF’s) provide some well understood regulation
mechanisms. Oxygen delivery to cells is essential for survival
of multicellular organisms and exquisite systems have evolved
to sense and adapt to changes in both global and local-cellular
oxygen concentration. One of these systems involves the HIF
proteins, whose oxygen tension regulated activity is required
as an essential part of development. Mice with targeted disrup-
tion of either HIF-1a or HIF-2a die of blood vessel malforma-
tion and for HIF-2a, potentially disrupted neurotransmitter
signalling and lung function (reviewed in [6]). In normoxic con-
ditions HIF-1a and HIF-2a (also known as HIF like factor
(HLF) or endothelial PAS factor (EPAS)) protein levels are rap-
idly turned over via the ubiquitin/proteasome pathway (re-
viewed in [6,7]). Hydroxylation at critical proline residues by
a family of prolyl hydroxylases (PHD 1, 2 and 3) enhances
recruitment of the von Hippel Lindau/E3 ubiquitin ligase com-
plex (VHL/E3 ligase) to aﬀect degradation by the proteasome
(reviewed in [6,7]). During periods of low oxygen tension, the
oxygen dependent PHD enzymes are unable to function,
recruitment of the VHL/E3 ligase is less eﬃcient, theHIF-a sub-
units are more stable and translocate to the nucleus. In the
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plexes that interact with transcriptional co-activators such as
CREB binding protein/p300 to activate target genes (reviewed
in [7]). Interaction with co-activator proteins is also regulated
by oxygen tension; in normoxia, hydroxylation of an asparagine
residue within the C-terminal transactivation domain, by a sep-
arate enzyme (factor inhibiting HIF-1), inhibits co-activator
recruitment (for review see [7]). Another layer of regulation ex-
ists whereby a novel bHLH/PAS factor termed inhibitory PAS
(IPAS) (inhibitory PAS, a splice variant of HIF-3a) is upregu-
lated in speciﬁc tissues in response to transient hypoxic condi-
tions (reviewed in see [7]). For example, it is proposed that
during sleep the cornea is exposed to hypoxia, triggering HIF-
1 activation and upregulation of target genes including IPAS.
IPAS lacks a C-terminal transactivation domain common to
the HIF-1 factors so far identiﬁed, and thus acts as a dominant
negative PAS factor, preventing upregulation of HIF-1 target
genes during periods of sleep and hence preventing aberrant
processes such as angiogenesis occurring in the eye.
1.3. Circadian rhythm proteins
A high proportion of the proteins involved in circadian
rhythm are PAS family members, including one of the found-
ing members of the PAS family: Period (PER). PER was iso-
lated from a mutant locus that altered the light/dark cycle
(circadian rhythm) of ﬂies (reviewed in [8]). Biological rhythms
are crucial elements in vertebrate biology and include the men-
strual cycle, hormone levels and circadian rhythm. Since the
initial cloning of PER, several PAS containing circadian fac-
tors have been cloned, which combine in a complex system
of positive and negative regulation to co-ordinate adaptive
molecular responses to external cues; a process known as
entrainment (reviewed in [8]). There exists a remarkable con-
servation between components of the systems in simple
eukaryotes, ﬂies and mammals (reviewed in [8]). Central to
the entrainment process are the PER proteins (PER 1-3),
Clock and BMAL (brain and muscle ARNT like protein) (re-
viewed in [8]). As PER proteins lack a DNA binding domain,
they are proposed to act as repressive proteins in this process
(reviewed in [8]). The circadian rhythm proteins perform gene
regulation via a combination of degradation of the signal sens-
ing units, regulated nuclear/cytoplasmic shuttling and a com-
plex interplay with negative acting factors, such as
cryptochromes and timeless. This generates a competition ef-
fect between various clock components, for the E-box regula-
tory elements located in the control regions of target genes
(reviewed in [8]). Two studies using high density and oligonu-
cleotide arrays have shown that there are approximately 600
genes regulated in a rhythmic manner in the circadian pace-
maker centre, the suprachiasmatic nucleus. Additionally, an
equally high number of genes appear to be regulated in periph-
eral tissue such as the heart and liver (for example see [9]).
1.4. ARNT
A valuable tool in the analysis of DR signalling has been the
murine hepatocellular carcinoma cell line Hepa1c1c7. Use of
mutant variants of these cells with an elegant series of comple-
mentation experiments led to the cloning of the Class II part-
ner factor, ARNT (reviewed in [1]). Subsequently, other
ARNT like factors have been identiﬁed including ARNT2
and BMAL/ARNT3 (for review see [1]). ARNT or ARNT likefactors are obligate partner factors for members of the bHLH/
PAS family. In vitro gel shift experiments and reporter gene as-
says demonstrate that ARNT also has the ability to function as
a homodimer by recognising the E-box element CACGTG (re-
viewed in [1]). Immunohistochemistry has demonstrated
ARNT to be nuclear localised in both cell culture systems
and in tissue sections [10,11]. However, an in vivo role for
ARNT independent of a Class I PAS family member remains
to be demonstrated. ARNT is ubiquitously expressed through-
out development in all tissues ([12] and references therein) and
is more ubiquitous in its expression than the other ARNT like
proteins. The circadian rhythm factor BMAL is expressed pri-
marily in the brain, heart and muscle [13] whilst ARNT2 is ex-
pressed predominantly in the brain and kidney [14]. Mice
which have a targeted disruption in the ARNT gene fail to pro-
gress past embryonic day 10.5 due to a defect in vascularisa-
tion [15], coincident with the phenotype of the HIF-1a
knockout (reviewed in [6]), demonstrating a crucial role for
ARNT in HIF-1a activity and indicating a lack of functional
redundancy between the ARNT proteins at this stage of devel-
opment. Recently, it has been demonstrated that both ARNT
and ARNT2 can act as partners for HIF-1a, but only ARNT
can serve as a partner for DR [16]. This raises the possibility
that adaptive responses might be further modulated through
diﬀerential partner selection.
1.5. Neuronal transcription factor (NXF)
NXF (also Npas4 – neuronal PAS domain protein 4) is a re-
cently identiﬁed brain speciﬁc member of the bHLH/PAS fam-
ily [17] that is immediately and potently upregulated in
ischaemia and seizure models ([18] and references therein).
NXF appears to regulate its own expression in a feed forward
mechanism, as well as activating Drebrin [17], a protein in-
volved in dendritic function, and may be important in response
to ischaemic stress.2. The dioxin receptor – a prototype bHLH/PAS factor:
stress and the rest
2.1. DR in the context of the organism
The DR is the only vertebrate member of the bHLH/PAS
family known to bind and be activated by small chemical
ligands. Many synthetic and naturally occurring planar poly-
aromatic xenobiotics can act as ligands, with the prototypical
agonist for the DR being 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD or dioxin) (for review see [19]). Most naturally occur-
ring ligands are of plant origin and are susceptible to meta-
bolism and excretion, although metabolism of some ligands
(e.g. the combustion derived benzo[a]pyrene) can produce
toxic compounds. Amongst the large numbers of known and
potential ligands, none are unequivocally endogenous, physio-
logical ligands. Much evidence, however, indicates endogenous
ligand(s) and/or activation mechanisms exist and this is
discussed elsewhere in this issue [20].
Toxicity of dioxin in humans remains controversial, however
both acute and chronic exposure leads to a range of toxic
responses in animal models. These include severe wasting
syndrome, chloracne, thymic involution, severe immune
suppression, reduced fertility, hepatotoxicity, teratogenicity,
tumour promotion and death [21]. Many xenobiotic meta-
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other ligand agonists) (reviewed in [19]), although dioxin itself
is not a substrate and is not metabolised or readily cleared
from the body (age and exposure dependent half-life in hu-
mans is up to 7 years (reviewed in [22]). Studies in DR null
mice ([23] and references therein), mice with targeted replace-
ment of DR with a nuclear localisation deﬁcient DR [24]
and the strong correlation between dioxin toxicity and intra-
species diﬀerences in DR aﬃnity provide compelling evidence
that the majority, if not all, of the toxic eﬀects of dioxin are
mediated by the DR ([23] and references therein).
Much evidence suggest that the DR has a role beyond adap-
tive response to xenobiotics. Evidence of developmental and
immune function, together with data suggesting that activation
can be independent of exogenous ligand, are discussed else-
where in this issue [20]. A number of genuine target genes that
do not ﬁt into a xenobiotic metabolising role have been iden-
tiﬁed, including Ecto-ATPase (an extracellular enzyme with a
possible role in the cell adhesion process), Adservin (a calcium
dependent actin binding protein), N-Myristoyltransferase 2
(responsible for addition of myristoyl groups and implicated
in regulating intracellular signalling) and Interleukin 2 (IL-2,
a cytokine critical for T-cell proliferation and survival) (re-
viewed in [22]). This has been expanded using gene expression
studies in which mRNA proﬁles were compared from livers of
DR+/+ and DR/ mice [25]. This analysis provides a list of
392 candidate DR dependent genes, whose expression is inde-
pendent of exogenous ligand [25]. These data support a model
in which the DR has roles, and cognate target genes, that
might be described as housekeeping and developmental as well
as an adaptive role in regulating the xenobiotic metabolising
gene battery. Housekeeping/developmental roles are proposed
to be independent of exogenous ligand, while adaptive roles
are exogenous ligand dependent integrating the idea that as-
pects of TCDD toxicities arise from aberrant, sustained activa-
tion of target genes outside the adaptive repertoire.
Microarray studies investigating the eﬀects of TCDD have
given diﬀerent data sets depending on tissue or cell type. These
studies have shown that while prototypical genes for xenobiotic
metabolism are globally induced, regulation of genes unrelated
to xenobiotic metabolism vary widely. Evidence from rodents
and zebraﬁsh suggests that toxicity does not result from persis-
tent upregulation of CYP1A1 levels (reviewed in [22]). Thus,
the complex range of toxicities might be explained by multifac-
torial aberrations, varying widely across diﬀerent tissues.
Much has been published on cross talk between DR and ER
(estrogen receptor) work by Ohtake et al. [26,27] has demon-
strated DR modulation of ER target gene activity by function-
ing as a transcriptional cofactor [26] and a component of a
ubiquitin ligase complex [27]. As a co-activator, DR forms
transcriptionally active complexes with unliganded ER on
ER target gene promoters [26]. This activity is modulated
through the DR’s ability to act as a adaptor in an E3 ligase
complex, an activity that is dependent on DR ligand [27]. It
has also been demonstrated that unliganded ER can function
as a co-activator for the DR [28,29]. These studies diﬀer in
the reported eﬀect that ER and estrogen have on the activity
of DR. It is clear that the ER can operate as a transcriptional
cofactor on the CYP1A1 promoter but it may depend on cell
line, and hence other factors, as to whether estrogen stimulated
ER enhances or represses transcription. These studies provideinsight as to how the pro- and anti-estrogenic eﬀects of dioxin
may occur, but raises the question of what the normal biolog-
ical function of this interaction is.
2.2. Regulation of DR activity
DR activation is regulated at several diﬀerent levels, the best
characterised of this regulation centring on the interaction of
the ligand binding domain of the DR with the molecular chap-
erone heat shock protein 90 (hsp90). Initial models proposed
that themajor mode of DR regulation was cytoplasmic localisa-
tion and hence compartmental isolation from the partner factor
ARNT [11] (and target gene enhancers). Ligand activation in-
vokes a nuclear translocation event, inferred to be the result of
a conformational change in theDR, exposing a nuclear localisa-
tion sequence located within the bHLH region (bipartite nuclear
localisation sequence (NLS) aa13–17 and 37–42 ofmDR (Figs. 2
and 3)) [30]. Upon entry into the nucleus, hsp90 is shed and the
DR heterodimerises with ARNT (Fig. 2). Subsequent to ARNT
dimerisation, DNA binding to XREs (Xenobiotic Response
Elements (minimal consensus TNGCGTG [31])) enables the
DR/ARNT complex to recruit basal transcription machinery,
transcriptional coactivators and chromatin remodelling en-
zymes, upregulating transcription of target genes (Fig. 2). Coac-
tivators and chromatin remodelling enzymes recruited by DR
include transcription initiation factor IIB, steroid receptor co-
activator 1, receptor interacting protein 140, brahma-related
protein 1, thyroid receptor interacting protein 230 (reviewed in
[32]), which bind deﬁned regions within the DR C-terminal re-
gion and coiled-coil co-activator (CoCoA) and GRIP1-associ-
ated co-activator 63 (GAC63) ([33] and references therein)
within the N-terminal region.
Several negative feedback systems exist to terminate DR sig-
nalling. In the case of metabolisable ligands, increased expres-
sion of xenobiotic metabolising enzymes eradicates the
activating ligand and thus removes the initiating stimulus.
Ligand activation also leads to targeting of the DR for ubiqui-
tin-mediated degradation (see [34] for review) however the se-
quences mediating this degradation remain to be determined.
The DR also contains two nuclear export sequences (NES)
that promote cytoplasmic localisation of the DR (Figs. 2 and
3). One present at the end of PAS-A (aa216–224 of mDR)
mediates nuclear export of unliganded receptor in a chromo-
some region maintenance protein 1 (CRM-1) dependent man-
ner (reviewed in [34]). The second, N-terminal, NES is present
in the bHLH (aa49–53 of mDR) mediates export of the ligand
activated receptor and thus acts to dampen DR signalling (re-
viewed in [34]). This NES conforms to a consensus CRM-1
recognition site, however, both CRM-1 dependent (reviewed
in [34]) and independent export [35] have been reported.
Whether these NES motifs regulate the degradation of the
DR by exporting it to the cytosol or whether the DR can be
degraded in the nucleus remain to be elucidated. In either case
the DR is rapidly depleted upon treatment with ligand [36]
providing additional damping of signalling. It is expected that
the DR will be subjected to post translational modiﬁcations to
control the various stages of its pathway, but these events are,
at this stage, ill deﬁned.
Charge heterogeneity of the DR has been known for a long
time and it has also been shown that this changes upon activa-
tion ([37] and references therein). In vitro dephosphorylation
of the DR/ARNT heterodimer completely abolishes DNA
BAB
AB
A B
A
AB
AB AB
CRM-1
AB
Dioxin Receptor
importin
ARNT
AB
HSP-90 dimer
XAP2
p23
Nuclear pore complex
Ligand binding
Nuclear Import
Nuclear export
and degradation
Concerted
exchange
?
Fig. 2. The DR pathway. The DR resides in the cytosolic compartment of the cell, bound to the molecular chaperones hsp90, XAP2 and p23. Ligand
activation of the DR invokes nuclear translocation via an N-terminal nuclear localisation sequence, transporting the DR into the nucleus by
interaction with importin a and moves through the nuclear pore complex (NPC). Once in the nucleus, the DR heterodimerises with the nuclear
partner factor ARNT to upregulate expression of xenobiotic metabolising enzymes in addition to the AhR repressor protein. During the activation
process, hsp90 is shed from the DR in a poorly understood mechanism. Following ligand activation the DR is targeted for degradation via the
addition of ubiquitin (Ub) and 26S proteasome mediated degradation. Shuttling between compartments also occurs.
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terminus (aa9 of mDR) of the DR to phenylalanine almost
completely abolishes DNA binding. This residue does not ap-
pear to be subject to phosphorylation ([39] and references
therein), but its mutation does aﬀect overall levels of DR phos-
phorylation. The tyrosine kinase inhibitor genistein completely
blocks transformation of DR to the DNA binding form, as
does in vitro treatment with tyrosine speciﬁc phosphatases
([40] and references therein). The tyrosine kinase c-src has been
implicated in regulation of DR activity [41], although there is
no evidence that DR is, in fact, phosphorylated by c-src. These
data are further confounded by the fact that bacterially ex-
pressed, and therefore non-phosphorylated, N-terminal frag-
ments of the DR and ARNT (corresponding to the bHLH
plus PAS-A) bind the XRE DNA response element with high
aﬃnity (0.4 nM) [42]. The serine/threonine kinase inhibitors
staurosporine [38] and LY294002 [43] have been reported to
block TCDD induced DNA binding and target gene activa-
tion, although others have reported varied eﬀects from stauro-
sporine [44,45]. Induction of PKC (protein kinase C) activityby PMA (phorbol 12-myristate 13-acetate) results in superin-
duction of a DR responsive reporter ([46] and references ther-
in). Some of this eﬀect may be due to an increase in the level or
activity of ARNT [3] and some may be due to stabilisation of
DR via PKC activation of Erk [47]. There is evidence for reg-
ulation of nuclear import and export by phosphorylation, with
PKC phosphorylation of residues adjacent the NLS (serines 12
and 36) inhibiting nuclear import and phosphorylation of ser-
ine 68 (possibly by the MAP kinase p38), adjacent the N-termi-
nal NES inhibiting nuclear export ([48] and references therein).
Phosphorylation of serines 36 and 68 have been conﬁrmed
using sequence speciﬁc anti-phosphoserine antibodies but no
other post-translational modiﬁcations have been positively
identiﬁed, although it seems likely that many exist. Interpreta-
tion of these data is made more complex due to the fact that
the unliganded DR exists in a complex of several proteins
(see later). In some instances these chaperone proteins may
be the target of regulation, emphasising the need to establish
what residues of the DR are subject to signal regulated post-
translational modiﬁcation.
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Fig. 3. Location of key domains and major protein interactions of the
DR. The size of domains and interactions is drawn to linear scale
proportional to amino acid number. The PAS domain and the PAS
cap structure, necessary for correct folding of this domain are shown.
The LBD illustrated corresponds to the consensus minimal LBD. The
DR interacts with a variety of regulatory proteins, of which the
interaction with hsp90 is the predominant interaction. Hsp90 binding
co-localises with the ligand binding PAS-B region of the DR. A range
of co-activators interact with the glutamine rich C-terminal activation
domain (Q-Rich (C-TAD) and only rudimentary data is available for
interaction of CoCoA and GAC63 in the N-terminal half of the DR
(N-TAD). Poorly characterised or questionable interactions are shown
with dashed lines, solid lines are well characterised interactions. See
text for references to the relevant interactions. NLS, nuclear localisa-
tion signal; NES, nuclear export signal; bHLH, basic-helix-loop-helix;
PAS, PER ARNT Sim homology domain.
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ulate DR transcriptional output. One of the target genes
upregulated by the DR encodes a protein that displays homol-
ogy to the N-terminal region of the DR but diverges after the
PAS-A domain. This protein has the ability to heterodimerise
with ARNT and bind the XRE (in vitro) and has been termed
the AhR repressor (AhRR, [49]) as overexpression of the
AhRR in cell culture systems ablates dioxin mediated reporter
gene induction [49]. The AhRR has been shown to be upregu-
lated both in vitro and in vivo upon exposure to the DR ligand
3-methylcholanthrene [49,50]. The AhRR promoter and adja-
cent regulatory sequence possess several XRE like sequences,
which, when mutated in combination, diminish the inducibility
of a reporter gene in transient transfection assays, implyingthat the repressor is indeed a bona ﬁde target gene of the DR
[50].2.3. Repression of DR activity through the LBD
The ligand binding domain of the DR sets this protein apart
from the other vertebrate members of the bHLH/PAS family.
It is a key region of regulation for the DR and understanding
this regulation is of particular interest.
The DR exists in the cytosol as a complex of several proteins
(reviewed in [51]). This complex includes the molecular chaper-
one hsp90, whose interaction maps to two distinct regions of
the DR (Fig. 3), a major binding region co-localising with
the ligand binding domain and a minor interaction mapping
to the N-terminal region which likely masks the bipartite
NLS ([30] and references therein), retaining the DR in the
cytoplasm. Aside from masking a nuclear localisation se-
quence, chaperone association is also thought to maintain
the DR in a form competent to bind ligand. This is validated
by the fact that the major hsp90 binding region of the DR
co-localises with the ligand binding region ([52] and references
therein), and in vitro translation of the DR in wheat germ ly-
sate (a system lacking a functional hsp90 homologue) produces
a form of the DR with poor aﬃnity for ligand ([53] and refer-
ences therein). Additionally, yeast strains with regulable levels
of hsp82 (the yeast homologue of hsp90) have been shown to
require hsp82 to restore DR signalling ([53] and references
therein). These studies demonstrate an absolute requirement
for hsp90 in DR signalling.
Upon ligand binding, the DR translocates from the cyto-
plasm to the nucleus and heterodimerises with ARNT
(Fig. 2). During this process, shedding of the molecular chaper-
one complex occurs, however, the sequence of events leading to
this ﬁnal outcome are poorly deﬁned. Several experimental ap-
proaches have demonstrated that ligand binding is inadequate
for hsp90 removal from the DR [54,55]. Studies demonstrate
that addition of ligand to in vitro translated DR is insuﬃcient
to release hsp90 from the DR but that ARNT is required in
the transformation mixture to induce DR/hsp90 release [54].
Further, evidence strongly suggests that the DR/chaperone
complex translocates to the nucleus [55], where hsp90 release
is concomitant with ARNT heterodimerisation (Fig. 2). This
latter suggestion is based on the rapid lability of the DR follow-
ing treatment with geldanamycin, an ansamyocin antibiotic
that inhibits the ATPase activity of hsp90 and dissociates
DR/hsp90 complexes [55], making it unlikely that unchaper-
oned DR exists within the cell. Additionally, nuclear localisa-
tion of the DR independent of ligand is insuﬃcient to shed
the molecular chaperones and invoke ARNT hetero-dimerisa-
tion [55]. Also, the studies using geldanamycin infer that a cor-
rectly structured LBD must be maintained and appropriately
derepressed in order to generate the structural integrity neces-
sary for a functional transcription factor. If the chaperones
are removed from the DR artiﬁcially then the DR is function-
ally inactive despite being able to heterodimerise with ARNT
and bind DNA [55]. The LBD appears to more broadly regu-
late DR activity because, whilst dioxin can fully invoke the
DR pathway through cytosolic-nuclear translocation to tran-
scriptional activation, there exist other ligands for the DR that
bind the DR but exhibit mixed abilities to progress the DR
along the activation pathway. For example 3-methoxy-4-nitrof-
lavone binds the DR but maintains the DR in a chaperone
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uent, has the ability to transform the DR to an ARNT bound
DNA binding complex but remains unable to activate tran-
scription [57]. This is not to say that the LBD domain per se
is essential for DRmediated transcription, as a deletion mutant
of the DR lacking the LBD (amino acids 287–421 of mDR) is
capable of ligand independent activation of target genes and
generates tumours in transgenic mice ([58] and references there-
in). The LBD, therefore, acts to repress DR function at a num-
ber of levels and can be derepressed in at least three distinct
manners: derepression resulting in nuclear localisation without
exchange of hsp90 for ARNT, derepression resulting in nuclear
localisation, exchange of hsp90 for ARNT, DNA binding with-
out apparent transactivation and, lastly, full derepression
resulting in nuclear localisation, exchange of hsp90 for ARNT
followed by DNA binding and transactivation of target genes.
Given there appear to be distinct developmental/housekeeping
and adaptive sets of target genes it is possible that alternative
mechanisms for LBD derepression conform the DR/ARNT
heterodimer for activation of diﬀerent genes.2.4. The role of co-chaperone proteins in DR signalling
In addition to hsp90, the DR has been shown by yeast two
hybrid and biochemical analysis to interact with an immuno-
philin like protein termed AIP (aryl hydrocarbon receptor
interacting protein; murine clone)/Ara9 (aryl hydrocarbon
receptor associated protein 9; human clone)/XAP2 (hepatitis
virus B X associated protein 2; simian clone) (reviewed in
[34]). Sequence alignment shows a loose homology between
XAP2 and FKBP52, the immunophilin associated with several
steroid hormone receptor complexes. Transient transfection
studies demonstrate an approximate twofold increase in
XRE driven reporter gene activity upon XAP2 coexpression
with the DR, correlating to an approximate twofold increase
in DR protein levels (reviewed in [34]). To this end XAP2 de-
creases ubiquitinated forms of the DR in transient overexpres-
sion experiments [59]. Furthermore DR chimeric proteins
fused to a ﬂuorescent tag suggest a role for XAP2 in cytosolic
retention for this protein (reviewed in [34]) Treatment of the
DR/chaperone complex in vitro with geldanamycin destabilizes
this complex such that p23 (see below) and XAP2 are lost from
the complex [60]. This supports the idea that XAP2 stabilizes
the DR/hsp90/p23 complex, preventing transient unmasking
of the N-terminal nuclear localisation sequence within the
DR and diminishing ligand independent nuclear accumulation
of the DR. Additionally, the presence of XAP2 in the latent
chaperone complex protects the DR from proteasome-medi-
ated degradation [59], an observation indicative of a stable
DR–chaperone complex. Evidence points to the DR undergo-
ing a process of chaperone loading similar to hormone recep-
tor systems, requiring a progression through several
intermediate (or immature) steps which are characterised by
the association of the DR with the molecular chaperones
hip, hop, hsp70, hsp90, p23 and XAP2 (reviewed in [34]). As
XAP2 interacts with both hsp90 and the DR (reviewed in
[34]) it is likely that XAP2 acts as a stabilising factor and the
presence of XAP2 in this complex may denote a subset of ma-
ture DR–chaperone complexes. Recent evidence from Hepa-1
cells conﬁrms that XAP2 functions to prevent nucleocytoplas-
mic shuttling, but that its depletion has no aﬀect on ligand in-
duced signalling in these cells [61]. Further, Hollingshead et al.[62] have addressed the apparent deﬁcit of XAP2 in hepato-
cytes using a transgenic model and demonstrate that, in these
cells, it is not limiting in terms of ligand induced DR activity.
This recent evidence supports a model in which XAP2 is dis-
pensable, however these studies have only addressed the role
of XAP2 in the context of DR’s response to xenobiotics within
hepatocytes leaving open its role in housekeeping and develop-
mental DR activities.
An additional factor in chaperone systems is a smaller co-
chaperone protein p23. This protein is an auxiliary factor for
hsp90 mediated chaperoning of steroid hormone receptor sub-
strates including the estrogen, androgen, glucocorticoid, thy-
roid and progesterone receptors ([63] and references therein).
p23 is expressed highly in the majority of murine tissues [63],
however p23 and a related protein (transcript similar p23)
are alternately expressed in diﬀerent tissues [63]. In both mam-
malian cell culture systems and a yeast reconstitution systems
the two forms of p23 can act in either identical or opposing
fashions, depending on the steroid receptor substrate [63].
The role of p23 in hsp90 mediated chaperone processes is
poorly understood but is proposed to facilitate the ATPase
activity of hsp90, however this is not due to an intrinsic in-
crease in ATPase activity of hsp90, rather p23 is proposed to
transmit the ATPase induced conformational change within
hsp90 more eﬃciently [64]. It appears that for several steroid
hormone signalling systems p23 is actually dispensable, as
has been demonstrated in vivo for the estrogen receptor in a
p23 depleted yeast strain [65].
Reconstitution studies in yeast utilising a p23 deletion strain
demonstrate that p23 augments the DR response but is not
essential for DR signalling [66]. It is not yet clear what role
p23 plays in DR signalling in mammalian cells. Studies focus-
sing on the DR have shown that p23 is associated with the DR
both in vitro and in vivo as the DR is immunoprecipitated with
antibodies directed against p23 using either in vitro translated
DR or using cell extracts ([60] and references therein).2.5. The DR: regulation at multiple levels but to what cause?
Even though poorly understood, it appears that the DR is
subject to a high degree of regulation to control transcriptional
activity. Given the importance of the other PAS family mem-
bers mentioned one could hypothesise that this reﬂects the
physiological importance of this protein. As mentioned above,
developmental expression studies, targeted disruption experi-
ments, recent advances in understanding the interactions with
the ER and the identiﬁcation of target genes outside the xeno-
biotic metabolism strongly support a role for the DR outside
xenobiotic metabolism.
Regulation of the DR hinges on its LBD. As yet, no crystal
structure for the LBD of the DR exists. This is presumably due
to the requirement of molecular chaperones for correct folding
of the LBD. In the absence of functional homologues in pro-
karyotes, large-scale preparation of this part of the protein
has not been possible. Until recently, a similar imposition ex-
isted for the GR. However, mutation of a single amino acid
within the ligand binding domain of the GR led to solubiliza-
tion of this region in a bacterial system and enabled the deri-
vation of a crystal structure [67]. Recently there have been
signiﬁcant advances in understanding the structure of PAS do-
mains [68] and of hsp90 and its client protein binding (for re-
view see [69]). We also have to revise our model of DR/ARNT
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PAS-A with the bHLH and possibly DNA itself [2]. These
new data suggest the DR adopts a compact structure with both
bHLH and PAS-A in close proximity with DNA (Fig. 2). The
structure and client binding of hsp90, along with our knowl-
edge of interaction sites between hsp90 and DR suggest that
the bHLH and PAS-B/LBD are in close proximity (Fig. 2).
If this were a direct interaction, this would provide a direct
means for ligand binding to aﬀect exposure of the NLS. It
may also explain the data on mutation of tyrosine 9, as this
residue might be involved in bHLH – PAS-B interaction,
rather than in DNA binding. Moreover, a compact structure
in which the LBD is forming an intramolecular interaction
with the bHLH and, perhaps, the transactivation domain
would allow diﬀerent modes of derepression to be transmitted
to the diﬀerent parts of the molecule. This sort of compact
arrangement accords with evidence about DR’s E3 ligase activ-
ity, in which interaction of the transactivation domain with
cullin4B is not only ligand dependent, but dependent on ligand
with full agonist activity [27]. This model has analogy in the
conformations the ER adopts depending on whether it is ago-
nist or antagonist bound. In the case of the ER, diﬀerent struc-
tures can recruit activator or co-repressor complexes [70].
Identiﬁcation of post-translational modiﬁcations of the DR,
particularly any that are signal regulated may also advance
the ﬁeld. Given evidence from other bHLH/PAS factors, nu-
clear hormone receptors and from within the DR ﬁeld, it is
likely that interaction with various components in the activa-
tion pathway will turn out to be regulated via post-transla-
tional modiﬁcation. It is also possible that regulated
post-translational modiﬁcations may be involved in ligand
independent derepression of the LBD.3. Future directions
Whilst signiﬁcant advancements in terms of documenting all
of the proteins that interact with and regulate the DR have
been made over the last several years, in reality our overall
understanding of how this regulation pieces together to coor-
dinate DR signalling and how this impacts on whole organism
physiology remains rudimentary. Early work has proposed
that these proteins act in a concerted eﬀort to control cellular
localisation, and maintenance of a form that is unable to het-
erodimerise with the partner factor in the absence of ligand.
Extension of studies on the physiological role of DR, in partic-
ular within the immune system where a wide range elegant
tools are available, are likely to provide signiﬁcant advances
in understanding both stress and housekeeping roles. Further-
more, it will be fascinating to identify the endogenous ligand
or activation mechanism. The biggest advances in the ﬁeld will
come when a link is made between the apparent alternate bio-
logical function of the DR during development and the mech-
anism(s) involved in its developmental activation as this will
close the loop on why the dysregulation of the adaptive re-
sponse results in such toxic responses.
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